EN | RU
EN | RU

Help Support

Back

OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse

OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse
OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse

To review the evidence of efficacy of OnabotulinumtoxinA (Botox) in chronic migraine (CM) with and without medication overuse, its limitations and key findings from prospective data from a tertiary headache clinic.

See All

Key take away

Although OnabotulinumtoxinA (Botox) is the only drug licensed for chronic migraine (CM) prevention, but its efficacy with analgesic overuse was still undermanaged. Hence, to know about CM with medication overuse, this study was employed which revealed beneficial results.

Background

To review the evidence of efficacy of OnabotulinumtoxinA (Botox) in chronic migraine (CM) with and without medication overuse, its limitations and key findings from prospective data from a tertiary headache clinic. CM is a disabling neurological condition, affecting around 2% of the general population with significant impact on quality of life and ability to work and perform activities of daily living. Botox is the only medication licensed for CM prevention. Its safety and efficacy has been shown in randomized controlled trial PREEMPT. However, it remains debatable as to whether patients with CM and analgesic overuse be subjected to withdrawal of overused medication before commencing preventive treatment.

Method

Patients that attended the Hull Migraine Clinic and received OnabotulinumtoxinA for chronic migraine were included. The patients were dived in those with and without medication overuse based on the International Headache Criteria. The data was collected through a dedicated headache diary.

Result

The Hull Migraine Clinic provides prospective real-life data on patients with CM treated with OnabotulinumtoxinA (Botox).

Conclusion

The data showed OnabotulinumtoxinA (Botox) to be equally effective in CM patients with and without medication overuse.

Source:

Curr Neurobio 2016; 7 (1): 13-15

Article:

OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse

Authors:

Alina Buture and Fayyaz Ahmed

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: